Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Acquired by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership increased its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 319.6% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 139,201 shares of the medical equipment provider’s stock after purchasing an additional 106,025 shares during the quarter. Artisan Partners Limited Partnership’s holdings in Intuitive Surgical were worth $47,598,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ISRG. RB Capital Management LLC raised its holdings in Intuitive Surgical by 4.4% during the first quarter. RB Capital Management LLC now owns 1,735 shares of the medical equipment provider’s stock worth $523,000 after purchasing an additional 73 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Intuitive Surgical by 0.6% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 946,709 shares of the medical equipment provider’s stock worth $285,603,000 after buying an additional 5,233 shares in the last quarter. Baird Financial Group Inc. increased its position in Intuitive Surgical by 2.3% during the first quarter. Baird Financial Group Inc. now owns 21,089 shares of the medical equipment provider’s stock worth $6,362,000 after buying an additional 481 shares in the last quarter. Brown Brothers Harriman & Co. grew its position in shares of Intuitive Surgical by 576.7% in the first quarter. Brown Brothers Harriman & Co. now owns 406 shares of the medical equipment provider’s stock valued at $122,000 after purchasing an additional 346 shares during the period. Finally, Covestor Ltd grew its position in shares of Intuitive Surgical by 50.4% in the first quarter. Covestor Ltd now owns 418 shares of the medical equipment provider’s stock valued at $126,000 after purchasing an additional 140 shares during the period. 82.91% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Stifel Nicolaus lifted their price objective on Intuitive Surgical from $315.00 to $350.00 and gave the company a “buy” rating in a research report on Friday. Morgan Stanley reduced their target price on Intuitive Surgical from $330.00 to $300.00 and set an “equal weight” rating on the stock in a report on Monday, October 23rd. Citigroup reduced their price objective on Intuitive Surgical from $400.00 to $390.00 and set a “buy” rating on the stock in a research note on Friday, October 20th. Royal Bank of Canada restated an “outperform” rating and set a $355.00 price objective on shares of Intuitive Surgical in a research note on Friday, October 20th. Finally, Raymond James reduced their price objective on Intuitive Surgical from $368.00 to $310.00 and set an “outperform” rating on the stock in a research note on Friday, October 20th. Five analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $342.71.

Intuitive Surgical Trading Up 0.4 %

NASDAQ:ISRG opened at $305.28 on Friday. The firm has a market capitalization of $107.48 billion, a PE ratio of 71.83, a price-to-earnings-growth ratio of 4.85 and a beta of 1.31. The stock has a 50 day moving average of $284.26 and a 200-day moving average of $305.09. Intuitive Surgical, Inc. has a 52 week low of $222.65 and a 52 week high of $358.07.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, October 19th. The medical equipment provider reported $1.46 EPS for the quarter, beating the consensus estimate of $1.40 by $0.06. The company had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.77 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 22.14%. The business’s revenue was up 12.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.90 earnings per share. As a group, analysts predict that Intuitive Surgical, Inc. will post 4.54 EPS for the current fiscal year.

Insider Activity

In other news, Director Amy L. Ladd sold 500 shares of the company’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $305.68, for a total transaction of $152,840.00. Following the completion of the transaction, the director now directly owns 702 shares of the company’s stock, valued at $214,587.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Amy L. Ladd sold 500 shares of the stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $305.68, for a total value of $152,840.00. Following the completion of the transaction, the director now directly owns 702 shares of the company’s stock, valued at approximately $214,587.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Robert Desantis sold 1,110 shares of the stock in a transaction that occurred on Tuesday, October 24th. The stock was sold at an average price of $273.49, for a total value of $303,573.90. Following the completion of the transaction, the executive vice president now directly owns 7,259 shares of the company’s stock, valued at $1,985,263.91. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 55,208 shares of company stock valued at $15,275,529. 0.90% of the stock is currently owned by insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.